Greater Uptake of Abbott/Eisai's Humira in the Treatment of Rheumatoid Arthritis and Crohn's Disease Will Drive Growth in the TNF-Alpha Inhibitor Market Through 2011
Posted on: Monday, 12 November 2007, 09:00 CST
WALTHAM, Mass., Nov. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the tumor necrosis factor-alpha (TNF-alpha) inhibitor market will experience robust 9% annual growth through 2011, driven by greater uptake of Abbott/Eisai's Humira in rheumatoid arthritis and psoriatic arthritis and its expansion into Crohn's disease and psoriasis.
The new Pharmacor report TNF-Alpha Inhibitors finds that, in addition to greater uptake of Humira, the rise of Amgen/Wyeth/Takeda's Enbrel in the psoriasis market and the launches of Centocor/Schering- Plough/Mitsubishi/Tanabe/Janssen's golimumab and UCB's Cimzia will also contribute to growth in the TNF-alpha inhibitor class. However, the increasing number of biologic agents targeting pathways other than TNF-alpha inhibition will stunt the growth of third-line TNF-alpha inhibitors, according to the report.
"In key indications, most notably rheumatoid arthritis and psoriasis, physicians will increasingly switch to biologic agents that offer different mechanisms of action after the failure of two TNF-alpha inhibitors," said Madhuri Borde, Ph.D., analyst at Decision Resources. "As a result, we forecast that market growth between 2011 and 2016 will slow to 3% annually as key market segments become saturated and lower-priced biogenerics erode brand sales."
About TNF-Alpha Inhibitors
Biologic therapies targeting tumor necrosis factor-alpha (TNF-alpha) are among the most effective agents available to treat a range of immune diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis. They are also among the most expensive therapies available to treat these diseases, and their high cost limits their use to a small minority of patients. Nevertheless, the market for TNF-alpha inhibitors will expand as currently marketed agents secure marketing approval for additional indications and as new agents emerge to compete with established drugs.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Alpha Natural Resources Announces Results for Third Quarter 2009
- Alpha Natural Resources Promotes Scott Pack to Chief Sales and Marketing Post
- Alpha Natural Resources and Foundation Coal Holdings Complete Merger, Creating One of America's Largest Coal Producers
- After Reviewing New Proxy Material of Alpha Natural Resources, Duquesne Capital Management Will Vote Against Proposed Merger with Foundation Coal Holdings
- Alpha Natural Resources Reports 60 Percent Improvement in Net Income for First Quarter
- Alpha Natural Resources Issues Updated Guidance for 2008; Subsidiary to Close Whitetail Kittanning Mine
- Alpha Natural Resources Announces That Its 2.375% Convertible Senior Notes Due 2015 Have Become Convertible
- Alpha Natural Resources Reports Strong Sales, Earnings Growth in First Quarter of 2008
- Alpha Natural Resources Reports Results for Fourth Quarter, Full Year 2006
- Crohn's Disease Drug Market to Experience Dynamic Growth of 73% By 2013
 |
 |
User Comments (0)
RSS Feeds